Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

289.39 +289.36 (+994367.35%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,061,497
Open	0.0290
Bid (Size)	290.12 (40)
Ask (Size)	302.85 (120)
Prev. Close	0.0291
Today's Range	285.22 - 292.98
52wk Range	283.10 - 495.55
Shares Outstanding	118,847,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts ↗

June 09, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst...

Via MarketBeat

Alnylam Pharmaceuticals (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Reasonable Valuation ↗

June 06, 2026

Via Chartmill

Performance

YTD	-27.7%	-27.7%
1 Month	-0.9%	-0.9%
3 Month	-8.8%	-8.8%
6 Month	-29.9%	-29.9%
1 Year	-3.1%	-3.1%

More News

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

June 03, 2026

From Alnylam Pharmaceuticals, Inc. and Inceptive

Via Business Wire

Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Alignment with the Little Book That Makes You Rich Growth Strategy ↗

June 01, 2026

Via Chartmill

Alnylam Issues 2025 Corporate Responsibility Report

May 19, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam’s First Billion-Dollar Quarter Smashes Q1 Estimates, ALNY Surges ↗

April 30, 2026

Via Chartmill

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build ↗

May 13, 2026

Via MarketBeat

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 07, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Strong Growth Fundamentals Align with a High-Probability Technical Setup ↗

April 24, 2026

Via Chartmill

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Emerges as a Top GARP Stock Pick ↗

April 18, 2026

Via Chartmill

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup ↗

April 01, 2026

Via Chartmill

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

May 04, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam (ALNY) Q1 2026 Earnings Transcript ↗

April 30, 2026

Via The Motley Fool

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

April 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

April 16, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

March 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

March 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast TTR Investor Webinar

March 10, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally ↗

March 05, 2026

Via Stocktwits

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?

Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market

What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?

The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 289.39

When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 06/11/26 04:00 PM ET

What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 34.39B

How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?

Alnylam Pharmaceuticals, Inc. - Common Stock has 34B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.